Minerva Neurosciences (NERV) Deferred Taxes (2016 - 2017)

Minerva Neurosciences (NERV) posted Deferred Taxes of -$6.6 million for Q3 2017, down 286.27% on a QoQ basis from $3.6 million in Q2 2017.

Minerva Neurosciences (NERV) Deferred Taxes (2016 - 2017) Analysis & Trends

Minerva Neurosciences' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$6.6 million for Q3 2017.

Quarterly Deferred Taxes changed N/A year-over-year to -$6.6 million in Q3 2017, while the trailing twelve-month figure through Dec 2017 was -$2.5 million (changed N/A YoY) and the FY2021 annual result came in at -$1.8 million, changed N/A from the prior year.
Deferred Taxes was -$6.6 million for Q3 2017 at Minerva Neurosciences, down from $3.6 million in the prior quarter.
Across five years, Deferred Taxes topped out at $3.6 million in Q2 2017 and bottomed at -$6.6 million in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Minerva Neurosciences	195.10 Mn	195.10 Mn	-	-

Download Data